BioSpace News Archive

Amidst a chorus of pushback from scientific and health organizations, Philip Morris International’s $1.4 billion offer now has the backing of Vectura Group’s board.

Ipsen announced, following very recent discussions with the U.S. Food and Drug Administration, withdrawal of the New Drug Application for palovarotene.

Transparency Market Research states that the competition in the global veterinary ultrasound scanners market is likely to intensify in the coming few years.

A recent market research report by TMR Research presents a thorough analytical account of the global metabolomics market.

The rising prevalence of kidney disorders and increasing popularity of kidney disorders and the rising cases of sepsis is projected to aid in expansion of the global continuous renal replacement therapy market.

Core One Labs Inc. is pleased to announce that its wholly owned subsidiaries, Rejuva Mental Health Clinic (“Rejuva”) and Bluejay Mental Health Group Inc. (“Bluejay”), have partnered to assist their patient with completing an application for exemption under section 56(1) of the Controlled Drugs and Substances Act (the “CDSA” or “Act”) of Canada for the purpose of legally accessing psilocybin for psychedelic-assisted therapy.

Protalix BioTherapeutics, Inc. announced the entry into definitive agreements relating to exchanges of an aggregate of $54.65 million principal amount of the Company’s outstanding 7.50% Senior Secured Convertible Notes due 2021 for an aggregate of $28.75 million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024, $25.90 million in cash, and accrued and unpaid interest through the closing date.

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), a vertically integrated, multi-state operator and the number one U.S. wholesaler of branded cannabis products, today announced its financial results for the second quarter ended June 30, 2021.

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent corporate developments.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, reported financial results for the second quarter ended June 30, 2021.